Congratulations to the authors for this novel approach to evaluating cumulative network-meta-analysis and practice guidelines as related to prescription patterns. This paper is very well-written with clear design and purpose. The results will be very interesting and I anxiously await reading the results.
prescriptions. I think that this is a very ambitious project and may represent a substantial contribution for the management of osteoporosis in post-menopausal women. The main concerns and clarifications needed are the following: -Methods and analysis -study identification and data extraction: a. please to clarify how many investigators will independently screen eligible original article. b. will there be any temporal or geographical limitation for the study selection? c. primary outcome: I agree with the Authors that hip fractures represent a strong determinant of patient's prognosis, however I would like to know why not consider also the bone mineral density variation as outcome? I think that this outcome may be of interest since it could give some indications on how to improve bone health before experiencing frailty fractures.
-"Comparisons of NMA rankings, CPG recommendations and real-world prescriptions" -time frame: since fracture risk is usually assessed every 18 months to 3 years (in absence of new fractures), I would retain that one year could be a too short time interval to detect a change in actual prescription after the publication of CPG recommendations.
- Table 1 : please to clarify this table, specifying the meaning of "RCTs to pool". Why did you chose to consider 1994, 1999, 2004, 2009 and 2014 as cut-offs for identifying RCT? How will you "isolate" the effect of CPGs of previous time-intervals on actual prescriptions? -Page 11, lines 219-223: It is not clear which analyses will be performed to compare the results from cumulative NMAs with CPG recommendations and actual prescriptions. Please to specify in the appropriate section.
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GENERAL COMMENTS
This manuscript is protocol for a study to compare the results of cumulative network meta-analysis with the recommendations in post-menopausal osteoporosis practice guidelines and with medical prescriptions. The paper is interesting and scientifically sound; however, I have some concerns about the methods for conduction the systematic search and the statistical analyses, which the author might want to consider: 1) Although the dates of the study are reported in the trial register platform under the number UMIN000031894, they should also be added in the manuscript. Also, update and complete the data in the platform to be consistent with the protocol presented in this manuscript. There are some information lacking in the platform.
2) Is unclear if you are actually planning to perform a complete systematic review by searching in electronic databases (e.g. MEDLINE, Scopus…) to retrieve the original articles, or if you will just include articles that you find in the guideline. Please add more information on how these steps will be performed and the possible search strategies that you will use. 
Response:
We greatly appreciate the encouragement. There are minor spelling mistakes and should be taken care of e.g. Line 63: "actial" should be replaced with "actual".
We have corrected the typo (page 4, line 64).
Overall the authors have proposed a defined protocol to address their aim of study.
We very much appreciate the positive comment. -Methods and analysis -study identification and data extraction:
a. please to clarify how many investigators will independently screen eligible original article.
We have added the following sentence in the Methods section (page 8, line 141).
Two of ten review authors independently examined each title and abstract identified in the search to exclude obviously irrelevant reports, then independently examine full-text articles to determine eligibility. If there were any disagreements, the same authors discussed disagreements; a third author helped reach consensus if necessary.
b. will there be any temporal or geographical limitation for the study selection?
We have added the following sentence in the Methods section (page 8, line 140).
We did not limit language, geographical location or publication date.. 
We appreciate the opportunity to clarify this point. We think only a true outcome should be included as the primary outcome of a systematic review and (network) meta-analyses [1]. Bone mineral density (BMD) is an important marker for decision to start treatment [2, 3] . However, it is a surrogate outcome.
Indeed, for BMD cannot predict fracture sufficiently [4] . Accordingly some clinical practice guidelines have made their recommendations based on outcomes other than BMD [3, 5] .
We apologize for our confusing description. We will compare the results summarized for every 5 years. We have added the following sentence in the Methods section (page 10, line 203).
The prescription proportions and rankings will be determined by the 5-year prescription proportion of each drug category.
(page 11, line 220).
We will compare results from cumulative NMAs with recommendations by CPGs and with actual prescriptions at 5-year intervals.
- Table 1 : please to clarify this table, specifying the meaning of "RCTs to pool".
Sorry for confusing remarks. We will pool RCTs published before the year of each cumulative NMA.
We have changed the caption as follows: MEPS started in 1996. So, we chose the first year of prescription ranking 1996.
We explained about the time lags in method (page 11 line 225).
First, because the median time from last search to publication of systematic reviews has been found to be 8.0 months (range: 0 to 47), we will include trials published up to 1 year prior to conducting the cumulative NMA.37 As there should be no time lag between the latest evidence synthesis and the CPG recommendations, we expect the NMA results to be reflected in the CPGs published in the ensuing five years. In 2000 a meta-epidemiological study showed a delay by 9.3 years between evidence review and its implementation.38 This delay may have been shortened in recent years.39 We will therefore compare the results from NMA and the CPG recommendations with actual prescriptions one or more years later than them.
We have added the following sentence in the Methods section (page 11, line 221).
MEPS started in 1996. We therefore chose 1996 as the first year of prescription ranking.
How will you "isolate" the effect of CPGs of previous time-intervals on actual prescriptions?
Response:
We agree that we cannot know the true effect of CPGs for actual prescriptions. We mentioned the limitation in the Discussion section as follows (page 13, line 265):
First, physicians' choice would be affected by reasons other than evidence, such as the policy of insurance companies or the marketing efforts of pharmaceutical company.40,41 These factors are difficult to quantify and will warrant a separate study. 
Response:
We have added the following sentences in the Methods section (page 12, line 234).
This is a descriptive study. We will visually explore the differences between evidences from NMA, CPG and actual prescriptions. We will not conduct statistical tests for comparison. 
Reviewer

Response:
We will cite the fixed protocol in the registration when published. Then we will update the date of protocol fixation. We have also added the following sentences in the Methods section (page 11, line 214).
We anticipate that we can start retrieving data in December 2018.
2)
Is unclear if you are actually planning to perform a complete systematic review by searching in electronic databases (e.g. MEDLINE, Scopus…) to retrieve the original articles, or if you will just include articles that you find in the guideline. Please add more information on how these steps will be performed and the possible search strategies that you will use.
Response:
We will not conduct a new systematic literature search to identify original randomized controlled studies but will use a recently completed search for relevant trials that we have conducted for a new guideline by the Endocrine Society about the management of osteoporosis. The guideline is not published yet. Accordingly, we have added the following sentences in the Methods section (page 7, line 125).
We will use a recently completed search for relevant studies (last search date: July 7 th 2017) that we have conducted for the guideline.
3)
Why you plan to include only FDA approved medications?
Response:
We intended to use MEPS which is the database of US. The database contains only FDA approved medications. But we could get the information about some medications without FDA approval from the guideline. We have modified in the Methods section (page 7, line 130) as follows:
iii) Trials evaluated commonly used medications including bisphosphonates, teriparatide, selective estrogen receptor modulators, denosumab, estrogen with or without progesterone, calcitonin, lasofoxifene, strontium ranelate, tibolone, or intact parathyroid hormone (PTH 1-84).
We will also include nutritional supplements commonly recommended for osteoporosis including calcium and vitamin D. Control conditions may include placebo, no treatment or treatment as usual.
4)
How do you plan to handle with "combination therapy" during the analyses?
Response:
Recent clinical practice guidelines do not recommend any combination drug therapy [6, 7] . We will simply count the number of patients prescribed each drug in MEPS.
In case the RCTs also include non-pharmacological intervention arms, what is going to be the procedure or analyses?
We will not consider non-pharmacological interventions. MEPS does not contain the information of non-pharmacological intervention.
5)
Why are you planning to include only parallel design RCTs?
In the case of treatments for osteoporosis, we anticipate only parallel design trials. Prevention of fractures due to osteoporosis would require long-term interventions and cannot be studied in a crossover design.
6)
Please add the reference to the paragraph on the risk of bias (methods sectionCochrane Risk of Bias tool). Only this step of your review will be performed independently by two reviewers?
Response:
We have added the reference.
Two of ten review authors independently examined each title and abstract identified in the search to exclude obviously irrelevant reports, then independently examine full-text articles to determine eligibility. If there were any disagreements, the same authors discussed disagreements; a third author helped reach consensus if necessary. The same independent pairs of reviewers also evaluated the risk of bias following the Cochrane risk of bias tool17.
7)
Why you already choose the random-effect cumulative NMAs? You should test other models.
Response:
Given the clinical and methodological heterogeneity of the populations and methods among the included trials in NMAs, we will use the random effects model in our primary analyses. We have explained this in the Methods section (page 8, line 158).
Given the clinical and methodological heterogeneity of the populations and methods among the included trials in NMAs, we will use the random effects model in our primary analyses.
8)
Are you using any priors for the NMAs? Are you planning additional sensitivity analyses? If so, please better clarify that in the manuscript
Response:
We will conduct the cumulative NMA in a frequentist framework using Stata and therefore no prior distributions and relevant sensitivity analyses will be employed. We have added the following sentences in the Methods section (page 9, line 172).
We will conduct the cumulative NMA in a frequentist framework using Stata and therefore no prior distributions and relevant sensitivity analyses will be employed.
9)
In the topic "Identification of practice guideline recommendations", which kind of information are you going to extract from the guidelines? Better clarify that in the text.
Response:
We have added the following sentence in the Methods section (page 9, line 182).
Two of the five independent authors (YK, YL, AO, MK, and YT) will extract data from each guideline. We will extract publication year, developers, recommendations and their strength, and whether the recommendations were based on systematic reviews or not. We will resolve disagreements through discussion and, if necessary, though arbitration by another author (YK, YL, AO, MK, or YT). 
10)
Response:
The answer is no. The systematic review included RCTs of postmenopausal women. The mean age of enrolled women across trials was 66 years. We think these minor difference of inclusion criteria will not affect the NMA results as heterogeneity.
